INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Fulgent Genetics, Inc. - FLGT

(MENAFN- GlobeNewsWire - Nasdaq) NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Fulgent Genetics, Inc. (“Fulgent” or the“Company”) (NASDAQ: FLGT). Such investors are advised to contact Danielle Peyton at ... or 646-581-9980, ext. 7980.

The investigation concerns whether Fulgent and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

On February 27, 2026, Fulgent issued a press release reporting its fourth quarter and full year 2025 financial results. Among other items, Fulgent provided lower-than-expected guidance for 2026,“reflect[ing] the impact of [its] largest customer moving a significant volume of its work in-house[.]”

On this news, Fulgent's stock price fell $9.43 per share, or 38.09%, to close at $15.33 per share on February 27, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See .

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
...
646-581-9980 ext. 7980

[Click here for information about joining the class action]

MENAFN03032026004107003653ID1110814384